|
Women with adverse outcomes N=261
|
Maternal age (years)
|
31
|
|
Women with adverse outcomes N=261
|
Gestational age at eligibillity (weeks)
|
33.9
|
|
Women with adverse outcomes N=261
|
Gestational age at eligibillity <34 weeks
|
133
|
|
Women with adverse outcomes N=261
|
Multiple pregnancy
|
36
|
|
Women with adverse outcomes N=261
|
Parity ≥1
|
72
|
|
Women with adverse outcomes N=261
|
Smoking during this pregnancy
|
26
|
|
Women with adverse outcomes N=261
|
Hypertension and proteinuria
|
178
|
|
Women with adverse outcomes N=261
|
Hypertension and hyperuricaemia
|
21
|
|
Women with adverse outcomes N=261
|
HELLP without hypertension or proteinuria
|
23
|
|
Women with adverse outcomes N=261
|
Superimposed pre-eclampsia
|
39
|
|
Women with adverse outcomes N=261
|
Peak: Mean arterial pressure (mmHg)
|
123
|
|
Women with adverse outcomes N=261
|
Peak: Systolic blood pressure (mmHg)
|
170
|
|
Women with adverse outcomes N=261
|
Peak: diastolic blood pressure (mmHg)
|
104
|
|
Women with adverse outcomes N=261
|
Worst dipstick proteinuria (+)
|
3
|
|
Women with adverse outcomes N=261
|
Lowest platelet count (x10^9/L)
|
170
|
|
Women with adverse outcomes N=261
|
Highest aspartate transaminase (U/L)
|
31
|
|
Women with adverse outcomes N=261
|
Corticosteroid administration
|
114
|
|
Women with adverse outcomes N=261
|
Antihypertensive drugs administered
|
214
|
|
Women with adverse outcomes N=261
|
MgSO4 administered
|
161
|
|
Women with adverse outcomes N=261
|
Admission-to-delivery interval, all cases (days)
|
2
|
|
Women with adverse outcomes N=261
|
Admission-to-delivery interval <34 weeks (days)
|
4
|
|
Women with adverse outcomes N=261
|
Gestational age at delivery (weeks)
|
34.7
|
|
Women with adverse outcomes N=261
|
Birthweight lower than third percentile
|
22
|
|
Women with adverse outcomes N=261
|
Intrauterine fetal death ≥20⁺⁰ weeks or ≥500 g
|
4
|
|
Women with adverse outcomes N=261
|
Neonatal death before 28 days
|
5
|
|
Women with adverse outcomes N=261
|
Infant death before hospital discharge or 6 weeks
|
7
|
|
Women without adverse outcomes N=1762
|
Maternal age (years)
|
31
|
|
Women without adverse outcomes N=1762
|
Gestational age ate eligibility (weeks)
|
33.9
|
|
Women without adverse outcomes N=1762
|
gestational age at eligibility <34 weeks
|
503
|
|
Women without adverse outcomes N=1762
|
Multiple pregnancy
|
156
|
|
Women without adverse outcomes N=1762
|
Parity ≥1
|
509
|
|
Women without adverse outcomes N=1762
|
Smoking during this pregnancy
|
223
|
|
Women without adverse outcomes N=1762
|
Hypertension and proteinuria
|
1164
|
|
Women without adverse outcomes N=1762
|
Hypertension and hyperuricaemia
|
303
|
|
Women without adverse outcomes N=1762
|
HELLP without hypertension or proteinuria
|
29
|
|
Women without adverse outcomes N=1762
|
Superimposed pre-eclampsia
|
266
|
|
Women without adverse outcomes N=1762
|
Peak: Mean arterial pressure (mm Hg)
|
120
|
|
Women without adverse outcomes N=1762
|
Peak: Systolic blood pressure (mm Hg)
|
160
|
|
Women without adverse outcomes N=1762
|
Peak: Diastolic blood pressure (mm Hg)
|
101
|
|
Women without adverse outcomes N=1762
|
Worst dipstick proteinuria (+)
|
2
|
|
Women without adverse outcomes N=1762
|
Lowest platelet count (x10^9/L)
|
194
|
|
Women without adverse outcomes N=1762
|
Highest aspartate transaminase (U/L)
|
26
|
|
Women without adverse outcomes N=1762
|
Corticosteroid administration
|
436
|
|
Women without adverse outcomes N=1762
|
Antihypertensive drugs administered
|
1167
|
|
Women without adverse outcomes N=1762
|
MgSO4 administered
|
529
|
|
Women without adverse outcomes N=1762
|
Admission-to-delivery interval, all cases (days)
|
2
|
|
Women without adverse outcomes N=1762
|
Admission-to-delivery interval, <34⁺⁰ weeks (days)
|
5
|
|
Women without adverse outcomes N=1762
|
Gestational age at delivery (weeks)
|
37.0
|
|
Women without adverse outcomes N=1762
|
Birthweight (g)
|
2685
|
|
Women without adverse outcomes N=1762
|
Birthweight lower than third percentile
|
143
|
|
Women without adverse outcomes N=1762
|
Intrauterine fetal death, ≥20⁺⁰ weeks or ≥500 g
|
16
|
|
Women without adverse outcomes N=1762
|
Neonatal death, before 28 days
|
15
|
|
Women without adverse outcomes N=1762
|
Infant death before hospital discharge or 6 weeks
|
19
|